Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Axel Grothey, Eric Van Cutsem, Alberto Sobrero et al. · The Lancet · 2012 · 2.9K citations

Medicine, Oncology, Pharmacology +10

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · The Lancet Oncology · 2014 · 1.7K citations

Medicine, Oncology, Pharmacology +9

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti et al. · The Lancet Oncology · 2015 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans

Ana Luiza Maia · Journal of Clinical Investigation · 2005 · 367 citations · Full text

Life Sciences, Biochemistry, Endocrinology +13

β-Catenin Regulates Deiodinase Levels and Thyroid Hormone Signaling in Colon Cancer Cells

Monica Dentice, Cristina Luongo, Raffaele Ambrosio et al. · Gastroenterology · 2012 · 109 citations · Full text

Life Sciences, Molecular Biology, Oncology +16